New trial
Phase II Trial: 177Lu Vipivotide Tetraxetan, PSMA-Directed Beta Emitter
- Trial ID
- NCT06894511 on ClinicalTrials.gov
- Cancer type
- Prostate Cancer
- Stage of research
- Exploratory
- Published in
- New in Oncology - June 27, 2025
This Phase II study randomizes men with PSMA-positive metastatic castration-resistant prostate cancer who progressed on prior ARPI to receive 6 cycles of 177Lu Vipivotide Tetraxetan either in combination with an androgen receptor pathway inhibitor or as monotherapy. Conducted by Novartis at multiple centers including Omaha, the trial evaluates improvements in radiographic progression-free survival.
More in prostate cancer
-
Trial result · Oct 22, 2026 · NCT03732820
Olaparib (PARP inhibitor) + Abiraterone (CYP17 AR-pathway inhibitor) Extends rPFS in Non‑BRCA mCRPC (PROpel) -
New trial · Oct 15, 2026 · NCT07813637
Phase 1 JANX013 PSMA×CD28 costimulation combines with JANX007 PSMA×CD3 T-cell engagement -
New trial · Oct 15, 2026 · NCT07832292
Phase 2 JNJ-101556143 uses an AR-BRD4 induced-proximity mechanism in resistant prostate cancer -
New trial · Oct 8, 2026 · NCT07824349
Phase 1a/1b JUR-003 KLK2×CD3 bispecific T‑cell engager in metastatic prostate cancer -
New trial · Oct 1, 2026 · NCT07803653
Phase 1 FH-STEAP1 IL-18 CAR T tests STEAP1-targeted CAR-T armored with IL-18